Description of Company and Basis of Presentation (Details)	1 Months Ended		3 Months Ended
	Nov. 30, 2016 Patient	Jul. 31, 2016 Patient ClinicalSite Country	Mar. 31, 2017
Description of Company and Basis of Presentation [Abstract]
Number of years Orphan Drug Designation provides several benefits of market exclusivity after approval			7 years
Number of years soft tissue sarcomas confers market among other benefits			10 years
Number of patients enrolled		433
Number of clinical sites | ClinicalSite		79
Number of countries | Country		15
Number of patients found to be statistically significant improvement in progression-free survival	246
Hazard ratio	0.62
Percentage of reduction in the risk of tumor progression	38.00%
Percentage of patients accounted to enrolled in the trial	57.00%
Number of patients treated	312
Percentage of total trial population	72.00%